A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension
Body Locations and Systems
Study Start/End Jul 16, 2020 to Apr 1, 2022
Mami Okada, Research Coordinator
Purpose of Study
The purpose of this study aims to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.